Fig. 1From: FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma73 year old man with imaging for metastatic cutaneous squamous cell carcinoma to the lung post 12 months of cemiplimab 350 mg/3-weekly. a demonstrating a CMR to treatment and (b) demonstrating ongoing RECIST1.1 PR with measurable disease on CTBack to article page